Compare ADMA Biologics Inc (ADMA) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Nano Dimension Ltd - ADR — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Nano Dimension Ltd - ADR trades at $1.67 (market cap $350.49M). The key difference: ADMA Biologics Inc is far larger — about 6.3× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | NNDM | |
|---|---|---|
Market Cap | $2.22B | $350.49M |
Sector | Health | Technology |
52-Week High | $20.38 | $2.14 |
52-Week Low | $7.60 | $1.21 |
Enterprise Value | $2.29B | -$54.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
NNDM trades at $1.67, up 2.45% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $121 million with a net loss of $163 million, reflecting a negative net margin of -135.18%. Recent strategic actions include selling non-core assets to reduce cash burn and appointing an interim CEO amid board restructuring.
The outlook remains challenged by persistent losses and high cash burn, though asset sales may improve liquidity. Investment opportunity hinges on successful execution of cost-saving initiatives and strategic refocusing. Key risks include ongoing operational losses, leadership transitions, and competitive pressures in the additive manufacturing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
